

Status	(All)
--------	-------

Drug Name	Tumour Group	Regimen Name on NCCP website	Regimen Number
5-Fluorouracil	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
		Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy
	5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)-Continuous infusion 7 day		421
	Aflibercept-14 days		238
	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day		446
	Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days		449
	CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen		460
	epiRUBicin, CISplatin and 5-FU (ECF) Therapy		240
	epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day		429
	FLOT Therapy-14 day		344
	FLOX Therapy		486
	FOLFIRI (14 days)+ Cetuximab (14 days) Therapy		585
	FOLFIRI (14 days)+ Cetuximab (7 days) Therapy		328
	FOLFIRI Therapy-14 day		227
	FOLFIRINOX Therapy		329
	FOLFOX-4 Therapy-14 day		210
	FOLFOXIRI Therapy		555
	Modified FOLFIRINOX Therapy		515
	Modified FOLFOX-6 Chemoradiation Therapy-14 day		509
	Modified FOLFOX-6 Therapy-14 day		209
	Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day		448
	Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day		447
	QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly		428
	Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days		502
	CISplatin, Infusional 5-Fluorouracil and Radiation Therapy		594
	Roswell Park Modified (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen		427
	5-Fluorouracil and Folinic Acid Therapy-14 day		660
	FOLFIRINOX Therapy - (Rectal Carcinoma)		691
	Cetuximab and FOLFOX-4 Therapy	692	
Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704		
Cetuximab and FOLFOX-6 (modified) Therapy	733		
Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783		

5-Fluorouracil	Gastrointestinal	Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	739	
		Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	816	
		Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	832	
		Pembrolizumab and FOLFOX-6 Modified Therapy	839	
		Nivolumab and FOLFOX-6 Modified Therapy	844	
		5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450	
	Head & Neck	Head & Neck	CARBOplatini (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle	552
			Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle	418
			Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/day Therapy- 21 day cycle	417
			CISplatin and 5-Fluorouracil Therapy-28 day	314
			DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324
			DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323
			CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy	589
			CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiotherapy	591
			Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy	705
			Pembrolizumab, CISplatin and 5-Fluorouracil Therapy	706
			DOCEtaxel (75), CISplatin (75), 5-Fluorouracil (1000), Chemoradiation and Surgery - Neoadjuvant (TCF)	315
Abiraterone	Genitourinary	Abiraterone 1000mg and Prednisolone 5mg Therapy	577	
		Abiraterone and Prednisolone Therapy	103	
Acalabrutinib	Leukaemia	Acalabrutinib Capsules Monotherapy	656	
		Acalabrutinib (Tablets) Monotherapy	840	
Afatinib	Lung	Afatinib Monotherapy	221	
Aflibercept	Gastrointestinal	Aflibercept-14 days	238	
Alectinib	Lung	Alectinib Monotherapy	401	
Alemtuzumab	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611	
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625	
		Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638	
Anastrozole	Breast	Anastrozole Monotherapy	254	
Apalutamide	Genitourinary	Apalutamide therapy	574	
Arsenic trioxide	Leukaemia	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357	
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356	
Atezolizumab	Breast	Atezolizumab and nab-PAClitaxel Therapy	688	
	Gastrointestinal	Atezolizumab and Bevacizumab Therapy	831	
	Genitourinary	Atezolizumab 1200mg Monotherapy	544	
		Atezolizumab 1680mg Monotherapy – 28 Day	593	
		Atezolizumab Monotherapy-14 day	592	
	Lung	Atezolizumab 1200mg Monotherapy	544	
		Atezolizumab 1680mg Monotherapy – 28 Day	593	
Atezolizumab Monotherapy-14 day	592			

Atezolizumab	Lung	Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689
	Lung	Atezolizumab 1200mg Monotherapy	544
Avelumab	Skin/Melanoma	Atezolizumab 1680mg Monotherapy – 28 Day	593
		Avelumab Monotherapy	535
Axicabtagene ciloleu	Lymphoma (CAR-T)	Axicabtagene ciloleu (Yescarta®) (CAR-T) DLBCL and PMBCL	717
Axitinib	Genitourinary	Axitinib Monotherapy	104
		Pembrolizumab 200mg and Axitinib Therapy	583
Azacitidine	Leukaemia	Azacitidine 100mg/m2 5-day Therapy	288
		Azacitidine 75mg/m2 5-2-2 Therapy	287
Azacitidine	Leukaemia	azaCITIDine (Oral) Monotherapy	818
Bendamustine	Lymphoma	Brentuximab vedotin and Bendamustine Therapy	529
		Obinutuzumab and Bendamustine Therapy-28 day cycle	424
		riTUXimab and Bendamustine Therapy	345
		Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy	685
	Leukaemia	Bendamustine Monotherapy	527
Bevacizumab	Breast	Bevacizumab 10mg/kg-14days	212
		Bevacizumab 15mg/kg - 21 days	215
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 Therapy	738
	Gastrointestinal	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446
		Bevacizumab 10mg/kg-14days	212
		Bevacizumab 15mg/kg - 21 days	215
		Bevacizumab 5mg/kg - 14 days	211
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		Bevacizumab 7.5mg/kg-21days	214
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day	
		Therapy- 21 day	623
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day	623
		Atezolizumab and Bevacizumab Therapy	831
	Genitourinary	Bevacizumab 10mg/kg-14days	212
	Gynaecology	Bevacizumab 10mg/kg-14days	212
		Bevacizumab 15mg/kg - 21 days	215
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day	499
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy	620
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2	716
Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy		766	
Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (day 1,8,15,22) Therapy		769	
Bevacizumab 10mg/kg and Topotecan 4mg/m2 therapy		771	
Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy		799	

Bevacizumab	Gynaecology	Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811
		Olaparib (Tablet) and Bevacizumab Therapy	746
		Bevacizumab 10mg/kg and Pegylated DOXOrubicin 40mg/m2 therapy	772
	Lung	Bevacizumab 15mg/kg - 21 days	215
		Bevacizumab 7.5mg/kg-21days	214
	Neuro-oncology	Lomustine and Bevacizumab 5mg/kg Therapy	742
		Lomustine and Bevacizumab 7.5mg/kg Therapy	804
Bevacizumab 5mg/kg Monotherapy – 14 Day		813	
(blank)	Bevacizumab 7.5mg/kg-21days	214	
Bicalutamide	Genitourinary	Bicalutamide Therapy	482
binimetinib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563
Bleomycin	Lymphoma	ABVD Therapy	290
		Escalated Dose BEACOPP 21 day Therapy	354
	Genitourinary/Gyn	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300
Blinatumomab	Paediatric Oncology	Blinatumomab Paediatric Therapy	P00567
		Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy	P00707
	Leukaemia	Blinatumomab Therapy	538
		Blinatumomab Therapy (ALL with MRD>0.1%	590
Bortezomib	Myeloma	Bortezomib , Melphalan and Prednisolone	275
		Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274
		Bortezomib and Dexamethasone Therapy	270
		Bortezomib Maintenance Therapy- 14 day	435
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416
		Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy	299
		Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day Therapy	273
		Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy	601
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day	643
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy	703
			752
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy	755
			756
		Bortezomib,Lenalidomide and Dexamethasone (RVD Lite) Induction Therapy	780
		Bortezomib and Lenalidomide RVD lite consolidation therapy	781
		AL Amyloidosis: cycloPHOSphamide, Bortezomib and dexAMETHasone (CVD) 28-Day Therapy	652
Bortezomib	Myeloma	Daratumumab (IV), bortezomib and dexamethasone therapy	560
		Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy	609

Bortezomib	Myeloma	Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy	695
Bosutinib	Leukaemia	Bosutinib Monotherapy	224
Brentuximab vedotin	Lymphoma	Brentuximab vedotin and Bendamustine Therapy	529
		Brentuximab vedotin and ESHAP therapy (BRESHAP)	530
		Brentuximab vedotin Monotherapy	234
		Brentuximab vedotin and ICE Therapy	528
		Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and prednisolONE (CHP) Therapy	801
	Leukaemia	Brentuximab vedotin Monotherapy	234
Lymphoma	Brentuximab vedotin Monotherapy	234	
Brigatinib	Lung	Brigatinib Therapy	562
Busulfan	Transplant	Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636
		Busulfan/Cyclophosphamide MAC-MUD	639
		Busulfan/Cyclophosphamide MAC-SIB	641
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor	662
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor	663
Cabazitaxel	Genitourinary	Cabazitaxel and Prednisolone	101
Cabozantinib	Genitourinary	Cabozantinib Therapy	518
Capecitabine	Breast	Capecitabine Monotherapy	216
		Lapatinib and Capecitabine	217
	Gastrointestinal	Capecitabine 825mg/m2 and RT–7 day	586
		Capecitabine and RT – 7 day	523
		Capecitabine and Temozolomide Therapy*	505
		Capecitabine Monotherapy	216
		Capecitabine/Oxaliplatin (XELOX) Therapy	321
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239
		Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days	524
		Gemcitabine + Capecitabine Therapy	384
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day	
		Therapy- 21 day	623
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691
		mitoMYcin and Capecitabine Chemoradiation Therapy	727
Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day	623		
CARBOplatin	Breast	CARBOplatin (AUC4-6) Monotherapy-21 days	261
		CARBOplatin (AUC4-6) Monotherapy-28 days	251
		CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple	
		Negative Breast Cancer Therapy	348
		DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258

CARBOplatin	Breast	Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430	
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722	
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731	
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775	
		DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy	789	
		Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)	790	
		Weekly CARBOplatin (AUC 2) and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734	
		CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	422	
	Gastrointestinal	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen	453	
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310	
		TICE -Autologous Conditioning Germ Cell Tumour Regimen	437	
		CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	419	
	Genitourinary	CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy	308	
		CARBOplatin (AUC4-6) Monotherapy-21 days	261	
		CARBOplatin (AUC4-6) Monotherapy-28 days	251	
		CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy	303	
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day	306	
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day	499	
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy	620	
		Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day	624	
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer	676	
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2	716	
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy	766	
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811	
		Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy	817	
		Head & Neck	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	419
			CARBOplatin (AUC4-6) Monotherapy-21 days	261
			CARBOplatin AUC (1.5) Chemoradiation Therapy-7 days	332
	CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle		552	
	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle		418	

CARBOplatin	Head & Neck	CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy	589
		CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiotherapy	591
	Lung	Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy	705
		CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561
		CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271
		CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy	304
		CARBOplatin and Oral Etoposide Therapy-21 days	319
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568
		PEMEtrexed and CARBOplatin Therapy	318
		Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy	309
		CARBOplatin and vinORELbine Therapy-21 Day	614
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689
	Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy	712	
	Lymphoma	Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy (R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	713
		Brentuximab vedotin and ICE Therapy	397
		ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	528
	Lymphoma	(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	842
			751
Carfilzomib	Myeloma	Carfilzomib (56mg/m2 once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
		Carfilzomib (20/70mg/m2 Once weekly) Dexamethasone (Kd) therapy - 28 day	595
Carfilzomib	Myeloma	Carfilzomib and Dexamethasone (Kd) Therapy - 28 day	566
		Carfilzomib (27mg/m2 twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	405
Carmustine	Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638
Carmustine (BCNU)	Lymphoma	BEAM Autologous Transplant Conditioning Protocol	408
Cemiplimab	Gynaecology	Cemiplimab Therapy	812
	Skin/Melanoma	Cemiplimab Therapy	812
Ceritinib	Lung	Ceritinib Monotherapy	340
Cetuximab	Gastrointestinal	Cetuximab (14 days) and Irinotecan (14 days) Therapy	331
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330
		Cetuximab Monotherapy-7 days	207
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		Cetuximab and FOLFOX-4 Therapy	692
		Cetuximab Therapy-14 days	732
Cetuximab and FOLFOX-6 (modified) Therapy	733		



Cetuximab	Head & Neck	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m <sup>2</sup> /day Therapy - 21 day cycle	418	
		Cetuximab (weekly), CISplatin 100mg/m <sup>2</sup> and 5-FU 1000mg/m <sup>2</sup> /day Therapy- 21 day cycle	417	
		Cetuximab Monotherapy-7 days	207	
Chlorambucil	Lymphoma	Chlorambucil10mg/m <sup>2</sup> Therapy	411	
	Leukaemia	Chlorambucil10mg/m <sup>2</sup> Therapy	411	
		Obinutuzumab and Chlorambucil Therapy	286	
CISplatin	Gastrointestinal	CISplatin 75mg/m <sup>2</sup> and 5-Fluorouracil Chemoradiation Therapy- Herskovic Regimen	460	
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473	
		CISplatin and Teysuno-28 day cycle	235	
		epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240	
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380	
		Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (25mg/m <sup>2</sup> ) Therapy- 21 day	383	
		Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502	
		CISplatin, Infusional 5-Fluorouracil and Radiation Therapy	594	
		Pembrolizumab 200mg, CISplatin 80mg/m <sup>2</sup> and 5-Fluorouracil Infusional Therapy	739	
		Nivolumab 240mg, CISplatin 80mg/m <sup>2</sup> and 5-Fluorouracil Infusional Therapy	816	
		Nivolumab 480mg, CISplatin 80mg/m <sup>2</sup> and 5-Fluorouracil Infusional Therapy	832	
		Genitourinary	CISplatin (40mg/m <sup>2</sup> ) Weekly with Radiotherapy (RT)	385
			CISplatin, Methotrexate and Vinblastine Therapy	337
			Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (70mg/m <sup>2</sup> ) Therapy- 28 day	282
			Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy	333
	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days		338	
	Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (35mg/m <sup>2</sup> ) Therapy- 21 day		622	
	Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (70mg/m <sup>2</sup> ) Therapy- 21 day		628	
	PACLitaxel, Ifosfamide, and CISplatin (TIP) Therapy		602	
	Gynaecology	CISplatin (40mg/m <sup>2</sup> ) Weekly with Radiotherapy (RT)	385	
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266	
		Two Day Etoposide CISplatin (EP) Therapy	267	
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264	
		CISplatin (50mg/m <sup>2</sup> ) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m <sup>2</sup> ) – Endometrial Cancer	676	
		Bevacizumab 15mg/kg, PACLitaxel 175mg/m <sup>2</sup> and CISplatin 50mg/m <sup>2</sup> Therapy	799	
		CISplatin (75mg/m <sup>2</sup> ) + Etoposide (100mg/m <sup>2</sup> ) + Radiotherapy (RT) - 21 day	279	
		Head & Neck	Cetuximab (weekly), CISplatin 100mg/m <sup>2</sup> and 5-FU 1000mg/m <sup>2</sup> /day Therapy- 21 day cycle	417
	CISplatin (100mg/m <sup>2</sup> ) with Radiotherapy (RT)		387	



CISplatin	Head & Neck	CISplatin (40mg/m2) Weekly with Radiotherapy (RT)	385
		CISplatin and 5-Fluorouracil Therapy-28 day	314
		DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324
		DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323
		Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day	517
		Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day	615
		Pembrolizumab, CISplatin and 5-Fluorouracil Therapy	706
		DOCEtaxel (75), CISplatin (75), 5-Fluorouracil (1000), Chemoradiation and Surgery - Neoadjuvant (TCF)	315
		Lung	CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day
	CISplatin (75mg/m2) + Etoposide Therapy-21 day		280
	Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day		281
	Pembrolizumab, PEMEtrexed and CISplatin Therapy		569
	PEMEtrexed and CISplatin Therapy		317
	Vinorelbine and CISplatin Therapy-21 days		339
	Vinorelbine and CISplatin Therapy-28 days		343
	CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day		279
	Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy		714
	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy		463
	Sarcoma	DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle	420
		CISplatin, Lomustine and vinCRISStine (CLV) Therapy	806
	Neuro-oncology	(R**)-DHAP Therapy	395
		Lymphoma	Brentuximab vedotin and ESHAP therapyi (BRESHAP)
	(R*)- ESHAP Therapy		394
riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)	441		
Genitourinary/Gyn	ESHAP Therapy	838	
	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300	
	Etoposide and CISplatin 20mg/m2 (EP) Therapy	301	
Cladribine	Leukaemia	Cladribine 0.14mg/kg Day 1 to 5 Therapy	402
		Cladribine 0.14mg/kg Weekly Therapy	469
	Leukaemia, Lymph	Cladribine 5 day and riTUXimab Therapy	531
Cladribine Weekly and riTUXimab Therapy		534	
Cobimetinib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373
Crizotinib	Lung	Crizotinib Monotherapy	243
cycloPHOSphamide	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269
		CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381

cycloPHOSphamide	Breast	Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378	
		DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485	
		Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433	
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252	
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260	
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432	
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263	
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262	
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745	
		Weekly CARBOplatin (AUC 2) and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734	
		Gynaecology	EMA/CO Therapy	248
		Head & Neck	Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day	615
	Sarcoma	Etoposide and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675	
			747	
	Lymphoma	(*riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRIStine and Prednisolone (*R)-CHOP Therapy– 14 days	409	
		(*riTUXimab), Cyclophosphamide VinCRIStine and Prednisolone (*R)-CVP) Therapy– 21 days	293	
		(R*)-CHOP – 21 days	307	
		(R**)- miniCHOP Therapy – 21 days	436	
		CHOEP Therapy– 21 days	396	
		Dose Adjusted R-EPOCH Therapy	355	
		Escalated Dose BEACOPP 21 day Therapy	354	
		Nordic Therapy	393	
		Obinutuzumab and CHOP Therapy – 21 day	549	
		obinutuzumab and CVP therapy -21 days	550	
		R-CEOP Therapy – 21 days	510	
		R-CODOX-M Therapy (Patients greater than 65 years)	403	
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398	
riTUXimab-HyperCVAD Therapy (MCL) – Part A		466		
Cyclophosphamide, DOXOrubicin, vinCRIStine and prednisoLONE (CHOP) Therapy– 21 days		841		

cycloPHOSphamide	Lymphoma	riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISTine and Prednisolone (R-CHOP) Therapy– 21 Days	667	
		Dose Adjusted R (S/C)-EPOCH Therapy	672	
		(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISTine and PrednisoLONE (*R)-GCVP) Therapy–21 days	737	
		Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and prednisoLONE (CHP) Therapy	801	
	Myeloma	Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy	299	
		Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day Therapy	273	
		AL Amyloidosis: cycloPHOSphamide, Bortezomib and dexAMETHasone (CVD) 28-Day Therapy	652	
	Lymphoma and M	Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation	438	
	Leukaemia	Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241	
	Lymphoma, Myelc	Cyclophosphamide 1500mg/m2 For Stem Cell Mobilisation	795	
	Lymphoma (CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL	606	
		Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)	608	
	Leukaemia (CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL	607	
	Transplant	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor	629	
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor	630	
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD	631	
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB	637	
		Busulfan/Cyclophosphamide MAC-MUD	639	
		Busulfan/Cyclophosphamide MAC-SIB	641	
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor	662	
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor		663		
Cyclophosphamide - Oral		Breast	Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
			Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy	532
	Leukaemia	Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410	
Cytarabine	Lymphoma	(R**)-DHAP Therapy	395	
		BEAM Autologous Transplant Conditioning Protocol	408	
		Brentuximab vedotin and ESHAP therapyi (BRESHAP)	530	
		High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508	
		LEAM Autologous Transplant Conditioning Protocol	468	
		Nordic Therapy	393	
		R-IVAC Therapy (Patients greater than 65 years)	404	

Cytarabine	Lymphoma	R-IVAC Therapy (Patients less than or equal to 65 years)	399
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467
		(R*)- ESHAP Therapy	394
		High Dose Cytarabine Consolidation Therapy (post RMPV) - 28 day Therapy	666
		ESHAP Therapy	838
	Leukaemia	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359
		FLAG:Ida 8mg/m <sup>2</sup> Therapy	362
		High Dose Cytarabine Therapy	365
		Intermediate Dose Cytarabine Therapy	364
		FLAG Therapy	363
		Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction)	612
		Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
	Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy	683	
Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638	
Dabrafenib	Skin/Melanoma	Dabrafenib Monotherapy	237
		Trametinib and Dabrafenib Therapy	415
Dacarbazine	Sarcoma	Dacarbazine (1.2 g/m <sup>2</sup> ) Therapy – 21 day	511
	Skin/Melanoma	Dacarbazine Therapy	464
	Lymphoma	ABVD Therapy	290
Dacomitinib	Lung	Dacomitinib Monotherapy	565
DACTINomycin	Gynaecology	DACTINomycin Therapy	247
		EMA/CO Therapy	248
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264
Darolutamide	Genitourinary	Darolutamide Therapy	693
Daratumumab	Myeloma	Daratumumab (IV), bortezomib and dexamethasone therapy	560
Daratumumab SC	Myeloma	Daratumumab Monotherapy	426
		Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy	609
		Daratumumab SC Monotherapy	604
		Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy	695
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy	703
			752
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy	755
			756
Daunorubicin	Leukaemia	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359
		Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction)	612
		Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
Decitabine	Leukaemia	Decitabine Monotherapy – AML (28 day cycle)	231

Degarelix	Genitourinary	Degarelix Therapy- 28 day	481	
Denosumab	Breast, Genitourin	Denosumab 120mg Therapy	741	
Dinutuximab beta	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548	
DOCEtaxel	Breast	DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250	
		DOCEtaxel Monotherapy 100mg/m2 – 21 day cycle	202	
		DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203	
		DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258	
		DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) Therapy - 21 day cycle	423	
		Pertuzumab + Trastuzumab + DOCEtaxel	204	
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722	
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731	
		DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy	789	
		Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - 21 day cycle	796	
		Gastrointestinal	DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203
			FLOT Therapy-14 day	344
		Genitourinary	DOCEtaxel 75mg/m2 - Prednisolone combination therapy	546
			DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203
		DOCEtaxel Monotheray 50mg/m2 Monotherapy-14 day	313	
	Gynaecology	DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203	
	Head & Neck	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324	
		DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323	
		DOCEtaxel (75), CISplatin (75), 5-Fluorouracil (1000), Chemoradiation and Surgery - Neoadjuvant (TCF)	315	
	Lung	DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203	
Nindetanib Therapy		372		
Sarcoma	Gemcitabine and DOCEtaxel Therapyi - 21 day	501		
DOXOrubicin	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485	
		Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433	
		DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) Therapy - 21 day cycle	423	
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252	
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260	

DOXOrubicin	Breast	DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745
		Weekly CARBOplatin (AUC 2) and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734
	Gastrointestinal	DOXOrubicin (60mg/m2) Therapy	386
	Genitourinary	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338
	Head & Neck	Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day (MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	615
	Sarcoma	DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle	463
		DOXOrubicin (60) and Ifosfamide Therapy	420
		DOXOrubicin (75) and Ifosfamide Therapy	391
		DOXOrubicin (75) and Ifosfamide Therapy	392
		DOXOrubicin 75mg/m2 Monotherapy	500
		Etoposide and ifosfamide - vinCRISline, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675
			747
	Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISline and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(R*)-CHOP – 21 days	307
		(R**) - miniCHOP Therapy – 21 days	436
		ABVD Therapy	290
		CHOEP Therapy– 21 days	396
		Dose Adjusted R-EPOCH Therapy	355
		Escalated Dose BEACOPP 21 day Therapy	354
		Nordic Therapy	393
		Obinutuzumab and CHOP Therapy – 21 day	549
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		Cyclophosphamide, DOXOrubicin, vinCRISline and prednisoLONE (CHOP) Therapy– 21 days	841
riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISline and Prednisolone (R-CHOP) Therapy– 21 Days		667	
Dose Adjusted R (S/C)-EPOCH Therapy		672	
Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and prednisoLONE (CHP) Therapy		801	
Durvalumab		Lung	Durvalumab 10mg/kg Monotherapy-14 Day
	Durvalumab 1500mg Monotherapy-28 Day		655
Encorafenib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563
Entrectinib	Lung	Entrectinib Therapy	702
Enzalutamide	Genitourinary	Enzalutamide Monotherapy	233
epiRUBicin	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265



epiRUBicin	Breast	5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269	
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263	
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262	
	Gastrointestinal	epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240	
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380	
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429	
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239	
Eribulin	Breast	EriBULLin Monotherapy	228	
		eriBULin Monotherapy – 28 Day	743	
Erlotinib	Lung	Erlotinib Monotherapy	219	
Etoposide	Genitourinary	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen	453	
		TICE -Autologous Conditioning Germ Cell Tumour Regimen	437	
		Gynaecology	EMA/CO Therapy	248
	PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy		266	
	Two Day Etoposide CISplatin (EP) Therapy		267	
	Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy		264	
	CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day		279	
	Lung		CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561
			CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271
		CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456	
		CISplatin (75mg/m2) + Etoposide Therapy-21 day	280	
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689	
		CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day	279	
		Sarcoma	Ifosfamide Etoposide (IE) Therapy	596
	Etoposide and ifosfamide - vinCRISTine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals		675	
			747	
	Lymphoma	(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397	
		BEAM Autologous Transplant Conditioning Protocol	408	
		Brentuximab vedotin and ESHAP therapy (BRESHAP)	530	
		CHOEP Therapy– 21 days	396	
		Dose Adjusted R-EPOCH Therapy	355	
		Escalated Dose BEACOPP 21 day Therapy	354	
		LEAM Autologous Transplant Conditioning Protocol	468	
		R-CEOP Therapy – 21 days	510	
		R-IVAC Therapy (Patients greater than 65 years)	404	
		R-IVAC Therapy (Patients less than or equal to 65 years)	399	
		SMILE Therapy (NK or T-cell lymphoma)	407	
(R*)- ESHAP Therapy		394		
Brentuximab vedotin and ICE Therapy		528		
Dose Adjusted R (S/C)-EPOCH Therapy		672		
ESHAP Therapy	838			



Etoposide	Lymphoma	ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842	
		(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	751	
	Genitourinary/Gyn	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300	
		Etoposide and CISplatin 20mg/m2 (EP) Therapy	301	
	Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638	
Etoposide Oral	Lung	CARBOplatin and Oral Etoposide Therapy-21 days	319	
		Oral Etoposide Therapy	388	
	Lymphoma	R-CEOP Therapy – 21 days	510	
Everolimus	Breast	Everolimus and Exemestane Therapy	322	
	Genitourinary	Everolimus Monotherapy	320	
	Neuroendocrine	Everolimus Monotherapy	320	
Exemestane	Breast	Everolimus and Exemestane Therapy	322	
		Exemestane Monotherapy	376	
Fedratinib	Leukaemia	Fedratinib Therapy	788	
Fludarabine	Leukaemia	FLAG:Ida 8mg/m2 Therapy	362	
			Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241
			Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410
			FLAG Therapy	363
	Lymphoma (CAR-T		Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL	606
			Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)	608
	Leukaemia (CAR-T		Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL	607
		Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625	
		Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635	
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636	
Folinic Acid	Gastrointestinal	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449	
		FLOT Therapy-14 day	344	
		FLOX Therapy	486	
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585	
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328	
		FOLFIRI Therapy-14 day	227	
		FOLFIRINOX Therapy	329	
		FOLFOX-4 Therapy-14 day	210	
		FOLFOXIRI Therapy	555	
		Modified FOLFIRINOX Therapy	515	
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509	
		Modified FOLFOX-6 Therapy-14 day	209	
		Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen	427	
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448	
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447	
		QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly	428	

Folinic Acid	Gastrointestinal	Roswell Park Modified (Fluorouracil 500mg/m <sup>2</sup> and Folinic Acid 50mg weekly x 6) Regimen	427	
		5-Fluorouracil and Folinic Acid Therapy-14 day	660	
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691	
		Cetuximab and FOLFOX-4 Therapy	692	
		Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704	
		Cetuximab and FOLFOX-6 (modified) Therapy	733	
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783	
		Pembrolizumab and FOLFOX-6 Modified Therapy	839	
		Lymphoma	R-CODOX-M Therapy (Patients greater than 65 years)	403
			R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
SMILE Therapy (NK or T-cell lymphoma)	407			
riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapyi	664			
Fulvestrant	Breast	Fulvestrant Therapy	361	
Gefitinib	Lung	Gefitinib Monotherapy	220	
Gemcitabine	Breast	Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430	
		Gastrointestinal	Gemcitabine (1000mg/m <sup>2</sup> ) and Capecitabine (830mg/m <sup>2</sup> ) Therapy - 28 days	524
	Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (25mg/m <sup>2</sup> ) Therapy- 21 day		383	
	Gemcitabine (1000mg/m <sup>2</sup> ) and RT therapy		521	
	Gemcitabine (1000mg/m <sup>2</sup> ) Monotherapy - 28 day		284	
	Gemcitabine (1000mg/m <sup>2</sup> ) Monotherapy - 56 day		283	
	Gemcitabine (400mg/m <sup>2</sup> ) and RT therapy		522	
	Gemcitabine (600mg/m <sup>2</sup> ) and RT therapy		559	
	Gemcitabine + Capecitabine Therapy		384	
	Nab-PACLitaxel (Abraxane®) and Gemcitabine – 28 day		256	
	Genitourinary		Gemcitabine (1000mg/m <sup>2</sup> ) and CARBOplatin (AUC 5) Therapy- 21 day	310
		Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (70mg/m <sup>2</sup> ) Therapy- 28 day	282	
		Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (35mg/m <sup>2</sup> ) Therapy- 21 day	622	
		Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (70mg/m <sup>2</sup> ) Therapy- 21 day	628	
	Gynaecology	Gemcitabine (1000mg/m <sup>2</sup> ) and CARBOplatin (AUC 4) Therapy- 21 day	306	
		Gemcitabine (1000mg/m <sup>2</sup> ), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day	499	
	Head & Neck	Gemcitabine (1250mg/m <sup>2</sup> ) and CISplatin (80mg/m <sup>2</sup> ) Therapy - 21 day	517	
		Gemcitabine (1250mg/m <sup>2</sup> ) Monotherapy - 21 day	514	
	Lung	Gemcitabine (1000mg/m <sup>2</sup> ) and CARBOplatin (AUC 5) Therapy- 21 day	310	
		Gemcitabine (1000mg/m <sup>2</sup> ) Monotherapy - 28 day	284	
		Gemcitabine (1250mg/m <sup>2</sup> ) and CISplatin (75mg/m <sup>2</sup> ) Therapy- 21 day	281	
	Sarcoma	Gemcitabine and DOCEtaxel Therapyi - 21 day	501	
	Lymphoma	R-Gemcitabine (1000mg/m <sup>2</sup> ) Oxaliplatin Therapyi - 14 day	506	
		riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)	441	

Gemcitabine	Lymphoma	(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISStine and PrednisoLONE (*R)-GCVP) Therapy–21 days	737
Gemtuzumab ozogamicin	Leukaemia	Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction)	612
Goserelin	Genitourinary	Goserelin 10.8mg-12 Weekly Therapy	477
		Goserelin 3.6mg Therapy- 4 weeks	478
Ibrutinib	Lymphoma	Ibrutinib Therapy (Mantly Cell Lymphoma)	297
	Leukaemia	Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)	296
Idarubicin	Leukaemia	FLAG:Ida 8mg/m2 Therapy	362
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366
Idelalisib	Lymphoma	Idelalisib Monotherapy	291
	Leukaemia	Idelalisib and Ofatumumab Therapy	390
		Idelalisib and riTUXimab Therapy	389
Ifosfamide	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
		PACLitaxel, Ifosfamide, and CISplatin (TIP) Therapy	602
	Sarcoma	DOXOrubicin (60) and Ifosfamide Therapy	391
		DOXOrubicin (75) and Ifosfamide Therapy	392
		Ifosfamide Etoposide (IE) Therapy	596
		Etoposide and ifosfamide - vinCRISStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675
		Infusional Ifosfamide Therapy	747
	Lymphoma	(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		SMILE Therapy (NK or T-cell lymphoma)	407
		Brentuximab vedotin and ICE Therapy	528
		ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842
		(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	751
	Imatinib	Sarcoma	Imatinib Therapy-GIST
Inotuzumab ozogamicin	Leukaemia	Inotuzumab ozogamicin Monotherapy	537
Ipilimumab	Gastrointestinal	Nivolumab 3mg Ipilimumab 1mg Therapy	551
	Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy	551
	Lung	Nivolumab 360mg and Ipilimumab 1mg/kg Therapy	792
		Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy	712
		Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy	713
		Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714
	Skin/Melanoma	Ipilimumab Monotherapy	105
		Nivolumab 3mg Ipilimumab 1mg Therapy	551
Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy		431	
Irinotecan	Gastrointestinal	Aflibercept-14 days	238
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		Cetuximab (14 days) and Irinotecan (14 days) Therapy	331
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328

Irinotecan	Gastrointestinal	FOLFIRI Therapy-14 day	227
		FOLFIRINOX Therapy	329
		FOLFOXIRI Therapy	555
		Irinotecan Monotherapy - 21 days	213
		Modified FOLFIRINOX Therapy	515
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Irinotecan 150mg/m2 Monotherapy - 28 days	654
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783
Isotretinoin	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548
Ixazomib	Myeloma	Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
Lapatinib	Breast	Lapatinib and Capecitabine	217
Larotrectinib	Tumour Agnostic	Larotrectinib Monotherapy - Adult	758
		Larotrectinib Monotherapy - Paediatric	P00760
L-Asparaginase	Lymphoma	SMILE Therapy (NK or T-cell lymphoma)	407
Lenalidomide	Myeloma	Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416
		Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
		Lenalidomide 25mg and Dexamethasone Therapy - 28 day	218
		Carfilzomib (56mg/m2 once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
		Carfilzomib (27mg/m2 twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	405
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day	643
		Bortezomib,Lenalidomide and Dexamethasone (RVD Lite) Induction Therapy	780
		Bortezomib and Lenalidomide RVD lite consolidation therapy	781
		Lenalidomide RVD lite Maintenance Therapy	782
Lenvatinib	Gastrointestinal	Lenvatinib -HCC Therapy	644
Lenvatinib	Head & Neck	Lenvatinib (Lenvima) -DTC Therapy	295
Letrozole	Breast	Letrozole Monotherapy	371
Leuprorelin	Genitourinary	Leuprorelin 3.75mg Therapy-28 day	494
		Leuprorelin 30mg Therapy- 24 weeks	493
		Leuprorelin 45mg Therapy- 24 week	491
		Leuprorelin 7.5mg Therapy- 28 day	490
		Leuprorelin 11.25mg Therapy- 12 weeks	492
Leuprorelin	Genitourinary	Leuprorelin 22.5mg Therapy- 12 weeks	479
Lomustine	Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy	379
		Procarbazine, Lomustine and VinCRISTine (PCV) Therapy – 56 days	658
		Lomustine and Bevacizumab 5mg/kg Therapy	742
		Lomustine and Bevacizumab 7.5mg/kg Therapy	804
		Lomustine 130mg/m2 Therapy	805
		CISplatin, Lomustine and vinCRISTine (CLV) Therapy	806
	Lymphoma	LEAM Autologous Transplant Conditioning Protocol	468
Lorlatinib	Lung	Lorlatinib therapy	570
Lutetium oxodotro	Gastrointestinal, n	Lutetium (177Lu) oxodotreotide (Lutathera®) Therapy	642
Melphalan	Lymphoma	BEAM Autologous Transplant Conditioning Protocol	408
		High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
		LEAM Autologous Transplant Conditioning Protocol	468

Melphalan	Myeloma	Bortezomib , Melphalan and Prednisolone	275
		High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625
		Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638
MESNA	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
	Lymphoma	SMILE Therapy (NK or T-cell lymphoma)	407
	Lymphoma and M	Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation	438
Methotrexate	Breast	Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338
	Gynaecology	EMA/CO Therapy	248
		Intrathecal Methotrexate for CNS Prophylaxis in GTN	249
		Methotrexate 8 day Charing Cross Regimen	246
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264
	Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463
		VinBLAStine and Methotrexate Therapy	554
	Lymphoma	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		SMILE Therapy (NK or T-cell lymphoma)	407
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467
		riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapyi	664
	Transplant	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor	629
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor	630
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD	631
		Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB	637
		Busulfan/Cyclophosphamide MAC-MUD	639
		Busulfan/Cyclophosphamide MAC-SIB	641
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor	662

Methotrexate	Transplant	Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor	663	
Methylprednisolone	Lymphoma	(R*)- ESHAP Therapy	394	
		ESHAP Therapy	838	
Midostaurin	Leukaemia	Midostaurin Maintenance Therapy	661	
		Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682	
		Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy	683	
Mifamurtide	Sarcoma	Mifamurtide	100	
mitoMYcin	Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451	
		mitoMYcin and Capecitabine Chemoradiation Therapy	727	
	Genitourinary	5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450	
Mogamulizumab	Lymphoma	Mogamulizumab Therapy	761	
Nab-PACLitaxel	Breast	Atezolizumab and nab-PACLitaxel Therapy	688	
Nab-PACLitaxel (Abraxane®)	Breast	Nab-PACLitaxel (Abraxane) Monotherapy-21 day cycle	230	
			736	
	Gastrointestinal	Nab-PACLitaxel (Abraxane®) and Gemcitabine – 28 day	256	
Nindetanib	Lung	Nindetanib Therapy	372	
Niraparib	Gynaecology	Niraparib Monotherapy	571	
Nivolumab	Genitourinary	Nivolulmab Monotherapy	349	
	Head & Neck	Nivolulmab Monotherapy	349	
	Skin/Melanoma	Nivolulmab Monotherapy	349	
	Lymphoma	Nivolulmab Monotherapy	349	
Nivolumab	Gastrointestinal	Nivolumab 3mg Ipilimumab 1mg Therapy	551	
		Nivolumab Monotherapy 240mg-14 day	483	
		Nivolumab Monotherapy 480mg-28day	484	
		Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	816	
		Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	832	
		Nivolumab and FOLFOX-6 Modified Therapy	844	
	Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy	551	
		Nivolumab Monotherapy 240mg-14 day	483	
		Nivolumab Monotherapy 480mg-28day	484	
	Head & Neck	Nivolumab Monotherapy 240mg-14 day	483	
		Nivolumab Monotherapy 480mg-28day	484	
	Lung	Nivolumab Monotherapy 240mg-14 day	483	
		Nivolumab Monotherapy 480mg-28day	484	
		Nivolumab 360mg and Ipilimumab 1mg/kg Therapy	792	
		Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy	712	
			Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy	713
			Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714
	Skin/Melanoma	Nivolumab 3mg Ipilimumab 1mg Therapy	551	
Nivolumab 3mg/kg Monotherapy		573		
Nivolumab Monotherapy 240mg-14 day		483		
Nivolumab Monotherapy 480mg-28day		484		
Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy		431		



Nivolumab	Lymphoma	Nivolumab Monotherapy 240mg-14 day	483	
		Nivolumab Monotherapy 480mg-28day	484	
Obinutuzumab	Lymphoma	Obinutuzumab and Bendamustine Therapy-28 day cycle	424	
		Obinutuzumab and CHOP Therapy – 21 day	549	
		obinutuzumab and CVP therapy -21 days	550	
		Obinutuzumab Maintenance Therapy -56 day	425	
	Leukaemia	Obinutuzumab and Chlorambucil Therapy	286	
	Leukaemia	Venetoclax and obinutuzumab Therapy	715	
Ofatumumab	Leukaemia	Idelalisib and Ofatumumab Therapy	390	
Olaparib	Genitourinary	Olaparib (Tablet) Monotherapy	588	
	Gynaecology	Olaparib (Tablet) Monotherapy	588	
		Olaparib (Capsule) Monotherapy	341	
		Olaparib (Tablet) and Bevacizumab Therapy	746	
Osimertinib	Lung	Osimertinib Monotherapy	353	
Oxaliplatin	Gastrointestinal	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Capecitabine/Oxaliplatin (XELOX) Therapy	321	
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429	
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239	
		FLOT Therapy-14 day	344	
		FLOX Therapy	486	
		FOLFIRINOX Therapy	329	
		FOLFOX-4 Therapy-14 day	210	
		FOLFOXIRI Therapy	555	
		Modified FOLFIRINOX Therapy	515	
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509	
		Modified FOLFOX-6 Therapy-14 day	209	
			Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
			FOLFIRINOX Therapy - (Rectal Carcinoma)	691
		Cetuximab and FOLFOX-4 Therapy	692	
		Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704	
		Cetuximab and FOLFOX-6 (modified) Therapy	733	
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783	
		Pembrolizumab and FOLFOX-6 Modified Therapy	839	
		Nivolumab and FOLFOX-6 Modified Therapy	844	
	Lymphoma	R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506	
PACLitaxel	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485	
		Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433	
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260	



PACLitaxel	Breast	DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432	
		PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512	
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507	
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226	
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621	
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 Therapy	738	
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745	
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775	
		Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)	790	
		Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therapy - 21 day cycle	797	
		PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	815	
		Weekly CARBOplatin (AUC 2) and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734	
		Gastrointestinal	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	422
			PACLitaxel Monotherapy 80mg/m2 7day	226
	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day		621	
	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437	
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226	
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621	
	Gynaecology	PACLitaxel, Ifosfamide, and CISplatin (TIP) Therapy	602	
		CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy	308	
		CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy	303	
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266	
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226	
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy	620	
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621	
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer	676	
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2	716	
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy	766	
	Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (day 1,8,15,22) Therapy	769		

PACLitaxel	Gynaecology	Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy	799
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811
		Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy	817
	Lung	CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy	304
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579
		Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy	309
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
		Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy	712
Palbociclib	Breast	Palbociclib Therapy-28 day	414
Panitumumab	Gastrointestinal	Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
		Panitumumab 6mg/kg Therapy	225
Pazopanib	Genitourinary	Pazopanib Therapy	445
	Sarcoma	Pazopanib Therapy	445
Pegylated Liposoma	Gynaecology	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
		Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day	624
		Bevacizumab 10mg/kg and Pegylated DOXOrubicin 40mg/m2 therapy	772
	Sarcoma	Pegylated Liposomal DOXOrubicin 20mg/m2 21 days	462
Pegylated Liposoma	Breast	Pegylated Liposomal DOXOrubicin 50mg/m2 28 days	205
	Gynaecology	Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day	624
		Pegylated Liposomal DOXOrubicin 50mg/m2 28 days	205
	Sarcoma	Pegylated Liposomal DOXOrubicin 50mg/m2 28 days	205
Pembrolizumab	Gastrointestinal	Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	739
		Pembrolizumab and FOLFOX-6 Modified Therapy	839
	Genitourinary	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab 200mg and Axitinib Therapy	583
	Gynaecology	Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811
		Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy	817
	Head & Neck	Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy	705
		Pembrolizumab, CISplatin and 5-Fluorouracil Therapy	706
	Lung	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568
Pembrolizumab, PEMEtrexed and CISplatin Therapy		569	
Skin/Melanoma	Pembrolizumab 200mg Monotherapy	455	

Pembrolizumab	Skin/Melanoma	Pembrolizumab 2mg/kg Therapy	347		
		Pembrolizumab 400mg Monotherapy	558		
	Lymphoma	Pembrolizumab 200mg Monotherapy	455		
		Pembrolizumab 400mg Monotherapy	558		
	Paediatric Oncology	Pembrolizumab Paediatric Monotherapy	P00711		
Head and Neck	Pembrolizumab 200mg Monotherapy	455			
PEMEtrexed	Lung	Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568		
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569		
		PEMEtrexed and CARBOplatin Therapy	318		
		PEMEtrexed and CISplatin Therapy	317		
		PEMEtrexed Monotherapy	222		
	Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy	713			
	Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714			
Pertuzumab	Breast	Pertuzumab + Trastuzumab + DOCEtaxel	204		
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350		
		Pertuzumab Trastuzumab and VinORELBine	526		
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507		
		Pertuzumab and Trastuzumab Therapy	726		
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722		
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731		
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775		
		Pertuzumab/Trastuzumab	Breast	Pertuzumab and Trastuzumab (Phesgo®) Maintenance Therapy	785
				DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy	789
Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)	790				
Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - 21 day cycle	796				
Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therapy - 21 day cycle	797				
Pertuzumab Trastuzumab (Phesgo®) and vinORELbine	798				
Pixantrone	Lymphoma	Pixantrone Therapy	255		
Plerixafor	Lymphoma, Myeloma	Plerixafor and G-CSF Therapy	536		
Polatuzumab vedotin	Lymphoma	Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy	685		
Pomalidomide	Myeloma	Pomalidomide and Dexamethasone	245		
Pomalidomide	Myeloma	Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy	601		
Ponatinib	Leukaemia	Ponatinib Therapy	302		
Procarbazine	Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy	379		
		Procarbazine, Lomustine and VinCRISTine (PCV) Therapy – 56 days	658		
	Lymphoma	Escalated Dose BEACOPP 21 day Therapy	354		
Radium 223	Genitourinary	riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapy	664		
		Radium 223 Therapy	257		

Regorafenib	Gastrointestinal	Regorafenib Monotherapy	244		
Relugolix	Genitourinary	Relugolix Therapy	830		
Ribociclib	Breast	Ribociclib Therapy-28 day	525		
riTUXimab	Lymphoma	(*riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISine and Prednisolone (*R)-CHOP Therapy– 14 days	409		
		(*riTUXimab), Cyclophosphamide VinCRISine and Prednisolone (*R)-CVP) Therapy– 21 days	293		
		(R*)-CHOP – 21 days	307		
		(R**)- miniCHOP Therapy – 21 days	436		
		(R**)-DHAP Therapy	395		
		(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397		
		Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy	532		
		Dose Adjusted R-EPOCH Therapy	355		
		High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508		
		Nordic Therapy	393		
		R-CEOP Therapy – 21 days	510		
		R-CODOX-M Therapy (Patients greater than 65 years)	403		
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398		
		R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506		
		riTUXimab 375 mg/m2 Combination Therapy-21 day	542		
		RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day	543		
		RiTUXimab 375 mg/m2 Maintenance Therapy-84 day	540		
		RiTUXimab 375 mg/m2 Therapy-7 day	541		
		RiTUXimab 375mg/m2 Therapy-Follicular Lymphoma	208		
		riTUXimab and Bendamustine Therapy	345		
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466		
		R-IVAC Therapy (Patients greater than 65 years)	404		
		R-IVAC Therapy (Patients less than or equal to 65 years)	399		
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467		
		(R*)- ESHAP Therapy	394		
		riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)	441		
		RiTUXimab (S/C 1400mg) Maintenance Therapy-84 day	599		
		RiTUXimab (S/C 1400mg) Maintenance Therapy-56 day	600		
		riTUXimab, Methotrexate, Procarbazine and vinCRISine (R-MPV) – 14 Days Induction Therapyi	664		
		riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISine and Prednisolone (R-CHOP) Therapy– 21 Days	667		
		Dose Adjusted R (S/C)-EPOCH Therapy	672		
		Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy	685		
		(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISine and PrednisoLONE (*R)-GCVP) Therapy–21 days	737		
		Leukaemia		Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241
				Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410
				Idelalisib and riTUXimab Therapy	389

riTUXimab	Leukaemia	Venetoclax and Rituximab therapy (R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	575
	Lymphoma	Cladribine 5 day and riTUXimab Therapy	531
	Leukaemia, Lymphoma	Cladribine Weekly and riTUXimab Therapy	534
Ruxolitinib	Leukaemia	Ruxolitinib Monotherapy	229
Sacituzumab Govitec	Breast	Sacituzumab Govitecan Therapy	794
Siltuximab	Lymphoma	Siltuximab Monotherapy	277
Sorafenib	Gastrointestinal	Sorafenib Therapy	294
	Genitourinary	Sorafenib Therapy	294
	Head & Neck	Sorafenib Therapy	294
Sunitinib	Genitourinary	SUNitinib 50mg Therapy (21 days)	719
	Sarcoma	SUNitinib 50mg Therapy (21 days)	719
Sunitinib	Genitourinary	Sunitinib 50mg Therapy	325
	Sarcoma	Sunitinib 50mg Therapy	325
	Neuroendocrine	Sunitinib 37.5mg Therapy	327
Talazoparib	Breast	Talazoparib Therapy	605
Tamoxifen	Breast	Tamoxifen Monotherapy	253
Temozolomide	Gastrointestinal	Capecitabine and Temozolomide Therapy*	505
	Neuro-oncology	Temozolomide Recurrent Therapy	342
		Temozolomide with Radiotherapy (RT) and Adjuvant Therapy- Patients greater than 65 years	461
		Temozolomide with RT and Adjuvant Therapy	334
Temsirolimus	Genitourinary	Temsirolimus Monotherapy	326
Teysuno	Gastrointestinal	CISplatin and Teysuno-28 day cycle	235
Thalidomide	Myeloma	Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy	703
			752
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy	755
			756
Thiotepa	Lymphoma	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
Tipracil	Gastrointestinal	Trifluridine and Tipiracil (Lonsurf®) Therapy	382
Tisagenlecleucel	Leukaemia (CAR-T	Tisagenlecleucel (Kymriah®) (CAR-T) B-ALL	686
	Lymphoma (CAR-T	Tisagenlecleucel (Kymriah®) (CAR-T) DLBCL	687
Tivozanib	Genitourinary	Tivozanib Therapy	564
Topotecan	Gynaecology	Topotecan Monotherapy-5 day	311
		Topotecan Monotherapy-Weekly	312
		Bevacizumab 10mg/kg and Topotecan 4mg/m2 therapy	771
	Lung	Topotecan Monotherapy-5 day	311
		Topotecan Oral Monotherapy	587
Trabectedin	Gynaecology	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
	Sarcoma	Trabectedin Monotherapy	374
Trametinib	Skin/Melanoma	Trametinib and Dabrafenib Therapy	415
Trastuzumab	Breast	Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775
	Gastrointestinal	Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704
Trastuzumab	Breast	PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	815

Trastuzumab emtar	Breast	Trastuzumab Emtansine (Kadcyla®) ) Early Breast Cancer Therapy- 21 days	659
Trastuzumab Emtansine (Kadcyla®)	Breast	Trastuzumab Emtansine (Kadcyla®) - 21 days	206
Trastuzumab IV	Breast	Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512
		Pertuzumab + Trastuzumab + DOCEtaxel	204
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350
		Pertuzumab Trastuzumab and VinORELBine	526
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507
		Trastuzumab (IV) Monotherapy 21 days	200
		Trastuzumab (IV) Monotherapy 7 days	201
		Pertuzumab and Trastuzumab Therapy	726
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745
		Trastuzumab SC	Gastrointestinal
Trastuzumab SC	Breast	Trastuzumab SC 21 days-Early Breast Cancer	285
Trastuzumab	Breast	Trastuzumab Subcutaneous 21 days- Metastatic Breast Carcinoma	272
		DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258
Trastuzumab IV	Breast	DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722
Trastuzumab SC	Breast	DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731
Tretinoin (ATRA)	Leukaemia	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366
Trifluridine	Gastrointestinal	Trifluridine and Tipiracil (Lonsurf®) Therapy	382
Triptorelin	Genitourinary	Triptorelin 11.25mg Therapy- 12 weeks	480
		Triptorelin 22.6mg Therapy- 24 weeks	488
		Triptorelin 3mg Therapy- 28 day	489
Vandetanib	Head & Neck	Vandetanib Monotherapy	242
Vemurafenib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373
		Vemurafenib Monotherapy	102
Venetoclax	Leukaemia	Venetoclax Monotherapy	400
Venetoclax	Leukaemia	Venetoclax and obinutuzumab Therapy	715
Venetoclax	Leukaemia	Venetoclax and Rituximab therapy	575



Vinblastine	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337	
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333	
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338	
	Sarcoma	VinBLAStine and Methotrexate Therapy	554	
	Lymphoma	ABVD Therapy	290	
VinCRIStine	Gynaecology	EMA/CO Therapy	248	
	Sarcoma	Etoposide and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675	
			747	
	Neuro-oncology	Procarbazine Lomustine and VinCRIStine (PCV) Therapy	379	
		Procarbazine, Lomustine and VinCRIStine (PCV) Therapy – 56 days	658	
		CISplatin, Lomustine and vinCRIStine (CLV) Therapy	806	
	Lymphoma	(*riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRIStine and Prednisolone (*R)-CHOP Therapy– 14 days	409	
		(*riTUXimab), Cyclophosphamide VinCRIStine and Prednisolone (*R)-CVP) Therapy– 21 days	293	
		(R*)-CHOP – 21 days	307	
		(R**)- miniCHOP Therapy – 21 days	436	
		CHOEP Therapy– 21 days	396	
		Dose Adjusted R-EPOCH Therapy	355	
		Escalated Dose BEACOPP 21 day Therapy	354	
		Nordic Therapy	393	
		Obinutuzumab and CHOP Therapy – 21 day	549	
		obinutuzumab and CVP therapy -21 days	550	
		R-CEOP Therapy – 21 days	510	
		R-CODOX-M Therapy (Patients greater than 65 years)	403	
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398	
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466	
		Cyclophosphamide, DOXOrubicin, vinCRIStine and prednisoLONE (CHOP) Therapy– 21 days	841	
		riTUXimab, Methotrexate, Procarbazine and vinCRIStine (R-MPV) – 14 Days Induction Therapyi	664	
		riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRIStine and Prednisolone (R-CHOP) Therapy– 21 Days	667	
		Dose Adjusted R (S/C)-EPOCH Therapy	672	
		(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRIStine and PrednisoLONE (*R)-GCVP) Therapy–21 days	737	
	Vinorelbine	Breast	Pertuzumab Trastuzumab (Phesgo®) and vinORELbine	798
		Lung	CARBOplatin and vinORELbine Therapy-21 Day	614
	Vinorelbine IV	Breast	Intravenous Vinorelbine Monotherapy-21day	232
			Pertuzumab Trastuzumab and VinORELBine	526
		Gynaecology	Intravenous Vinorelbine Monotherapy-21day	232
		Lung	Intravenous Vinorelbine Monotherapy-21day	232
			Vinorelbine and CISplatin Therapy-21 days	339
		Vinorelbine and CISplatin Therapy-28 days	343	
Vinorelbine Oral	Breast	Oral Vinorelbine Monotherapy-7days	259	
	Lung	Oral Vinorelbine Monotherapy-7days	259	
Vismodegib	Skin/Melanoma	Vismodegib Monotherapy	236	



Vyxeos liposomal®	Leukaemia	Vyxeos liposomal® (DAUNOrubicin and cytarabine) Induction Therapy	613	
		Vyxeos liposomal® (DAUNOrubicin and cytarabine) Consolidation Therapy	618	
Zanubrutinib	Lymphoma	Zanubrutinib Therapy	708	
Zoledronic acid	Breast	Zoledronic acid monotherapy	545	
		Breast, Genitourin	Zoledronic Acid Therapy-28 days	723
			Zoledronic Acid Therapy-3 monthly	724
			Zoledronic Acid Therapy-6 monthly	725